28P6/E6

Drug Profile

28P6/E6

Latest Information Update: 07 Feb 2008

Price : $50

At a glance

  • Originator Viventia Biotech
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 04 Apr 2003 No development reported - Preclinical for Cancer in Canada (unspecified route)
  • 09 Jan 2001 New profile
  • 09 Jan 2001 Preclinical development for Cancer in Canada (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top